Soliris (eculizumab) prevented disease recurrence in a small group of patients with primary atypical hemolytic uremic syndrome (aHUS) after they underwent kidney transplantation, a recent study has found. The study, “Efficacy and Safety of Eculizumab in Kidney Transplant Patients With Primary Atypical Hemolytic-Uremic Syndrome,” was published in…
News
By shortening the time spent on treatment, Ultomiris (ravulizumab), an approved therapy for atypical hemolytic uremic syndrome (aHUS), may be more effective at reducing lost productivity costs compared with its predecessor Soliris (eculizumab), according to a new study. The study, “Quantifying the economic effects of ravulizumab…
Because viral infections can worsen atypical hemolytic uremic syndrome (aHUS), researchers recommend testing patients for infections that are common following an organ transplant. They describe the case of patient, whose aHUS symptoms recurred after undergoing a kidney transplant, in their report, “Concurrent cytomegalovirus enteritis and atypical…
C5a, a terminal product of the complement system, can, by itself, promote blood vessel dysfunction and the subsequent formation of blood clots seen in people with atypical hemolytic uremic syndrome (aHUS), a study shows. Notably, the same C5a-induced molecular mechanisms were detected among patients with severe COVID-19 and whose infection…
For this year’s Rare Disease Day on Feb. 28, the aHUS Alliance is asking patients and caregivers to join them in their project to showcase questions from those affected by atypical hemolytic uremic syndrome (aHUS). This project is aimed at raising awareness for those affected by aHUS.
Two newly reported mutations in a complement-related gene appear to have triggered atypical hemolytic uremic syndrome (aHUS) in a woman within months of a kidney transplant, according to a case report. The report, “A novel Atypical hemolytic uremic Syndrome–Associated CFH gene in a renal transplant recipient complicated with ileum perforation,”…
Samsung Bioepis announced that its product SB12, a proposed biosimilar — a product that is highly similar, with no clinically meaningful differences, to an original patented product — to Soliris (eculizumab), showed equivalent properties with regards to the therapy’s safety, pharmacokinetics, and immune profile in a…
About four in 10 children in Egypt who have atypical hemolytic uremic syndrome (aHUS) test positive for antibodies against the complement protein factor H, a study has found. These findings highlight the importance of testing for the presence of these antibodies to ensure prompt diagnosis and treatment, according to…
Some COVID-19 patients may develop severe atypical hemolytic uremic syndrome (aHUS), but it can be completely or partly resolved with Soliris (eculizumab), according to three cases reported in a recent study. These cases add to a few other aHUS cases reported to be likely triggered by COVID-19,…
Plasma exchange and treatment with Soliris (eculizumab) may be used successfully to treat pregnancy-related atypical hemolytic uremic syndrome (aHUS) complicated by kidney failure, a case report suggests. The report, “Atypical hemolytic uremic syndrome: when pregnancy leads to lifelong dialysis: a case report and literature review,” was published in…
Recent Posts
- Unexpected gene therapy finding may help treat two rare kidney diseases
- How aHUS treatment led to my first tattoos
- Ultomiris at lower doses just as safe, effective for children with aHUS: Study
- Strange symptoms make me wonder if I’m having neurological complications
- Leaky artificial heart valve triggers rare aHUS in woman, 70: Report
- How my body naturally reacts to one of my bad habits
- Study finds alternative pathway is main driver of aHUS
- Rapid, sustained aHUS response seen with Ultomiris in real-world data
- Team care saves mother with trio of postpartum complications
- Once a good side hustle, donating plasma is now too risky for me